|
|
Matthew |
|
Segall |
|
CEO |
Optibrium |
https://proventainternational.com/wp-content/uploads/2020/02/Matt-Segall2-1-1-e1648136474893.jpg |
Matthew Segall is CEO of Optibrium. He has an MSc in Computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. Since 2001, Matthew has led teams developing predictive models and intuitive decision-support and visualization tools for drug discovery. In 2009 he led a management buyout of the StarDrop™ business to found Optibrium, which develops novel technologies and ground-breaking AI software and services, including Cerella™ and Inspyra™, that improve the efficiency and productivity of drug discovery. |
|
|
Scott |
|
McDonald |
|
Director of Business Development |
Optibrium |
https://proventainternational.com/wp-content/uploads/2022/03/Scott-M-1-e1648136938961.jpg |
Scott is a Director of Business Development at Optibrium Limited based in the UK. He gained an MChem in Chemistry with
Medicinal Chemistry from the University of Salford in 1999.
Scott works with scientists to help them to make scientifically robust decisions through the application of software to the discovery and development process. He spent nearly 20 years with Lhasa Limited, an organisation that develops predictive in silico methodologies, predominantly in the field of toxicology. In 2021 he joined Optibrium to help scientists take advantage of Optibrium’s leading software packages to deliver optimally balanced, successful compounds, quickly. |
|
|
Dave |
|
Madge |
|
VP WuXi Discovery Services |
WuXi AppTec |
https://proventainternational.com/wp-content/uploads/2022/04/Dave-Madge.jpg |
Over 20 years’ experience working within academia, biotech and CROs. Former VP Research at Xention, founder of NCE Discovery (now Domainex) and a member of the integrated biomedical research group at University College London. Dave started his career at the Welcome Foundation and received his Ph.D in Chemistry from Imperial College, London. |
|
|
Andreas |
|
Bender |
|
Professor, Molecular Informatics |
University of Cambridge |
https://proventainternational.com/wp-content/uploads/2022/01/andreas-bender.jpeg |
|
|
|
Roland |
|
Bürli |
|
VP, Chemistry |
Cerevance |
https://proventainternational.com/wp-content/uploads/2022/01/Roland-Burli-New.jpg |
Roland Bürli is VP of Drug Discovery at Cerevance, a Cambridge UK based Biotech, dedicated to the discovery of novel therapeutics for grievous CNS diseases. Roland joined Cerevance three years ago from AstraZeneca’s Neuroscience group and prior to this, he worked in drug discovery in several Biotech and large Pharma in the USA and the UK. His core expertise is in medicinal chemistry. He did a doctorate in chemistry at ETH and was a postdoctoral fellow at Caltech. Roland co-authored over 100 peer-reviewed publications and patents. |
|
|
Ian |
|
Churcher |
|
Chief Scientific Officer |
Amphista Therapeutics Limited |
https://proventainternational.com/wp-content/uploads/2022/04/Ian-Churcher.jpg |
|
|
|
Werngard |
|
Czechtizky |
|
Executive Director, Head of Medicinal Chemistry, Respiratory and Immunology |
AstraZeneca |
https://proventainternational.com/wp-content/uploads/2020/08/Werngard-Czechtizky-Edited-1-scaled.jpg |
Werngard Czechtizky is Head of Medicinal Chemistry for Respiratory & Immunology at AstraZeneca. She has a track record of delivery of clinical candidates and lead compounds across several therapeutic areas (CV, Diabetes, Pain, CNS, Aging, Respiratory and Immunology). She implemented state of the art technologies into Medicinal Chemistry, e.g. ML/AI tools, New Modalities, chemical probes for target validation, automated synthesis and integrated physchem & eADME profiling workflows. Werngard serves on diverse scientific advisory boards and is co-/author of >100 publications and patents. She has studied at the Technical University of Graz, Austria, received a PhD from ETH Zürich and a postdoctoral training at Harvard University. Before joining AZ in 2017, she has been working at Aventis, then Sanofi at Frankfurt, Germany. |
|
|
Matthew |
|
Fyfe |
|
Chief Scientific Officer |
Outrun Tx |
https://proventainternational.com/wp-content/uploads/2020/04/Matthew-Fyfe-1.jpg |
|
|
|
Abdul |
|
Hamid Merii |
|
Machine Learning Engineer |
Silence Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/05/Abdul-Hamid.jpg |
Bachelor’s in Mechanical Engineering and Masters in Robotics and Mechatronics. Experience training machine learning models on multi-temporal satellite imagery for the purpose of building footprint change detection. Currently working on optimising oligonucleotide drug design using machine learning. |
|
|
Robert |
|
Heald |
|
VP, Chemistry |
Artios Pharma |
https://proventainternational.com/wp-content/uploads/2022/01/Robert-Heald-scaled-e1641398144693.jpg |
Robert Heald is a Medicinal Chemist with over 20 years of industrial experience and currently VP of Chemistry at Artios Pharma, a leading clinical stage UK Biotech company focussed on the exploiting therapeutic opportunities in the DNA damage response for the treatment of cancer.
Before joining Artios Rob was a Director of Chemistry at Argenta Discovery (latterly Charles River) where he managed a group of over 30 chemists and led teams and projects in collaborations with a wide range of institutions from Universities to large Biotech and Pharma. These collaborations included 10 years with Genentech and 5 years with Chiesi. During this time his teams were responsible for the discovery of 6 clinical candidates for oncology and respiratory indications, the most advanced of which is now in Phase III clinical studies.
Since joining Artios in 2016 shortly after Series A fundraising Rob has led the medicinal chemistry team responsible for delivering the first human DNA polymerase inhibitor to enter clinical trials, ART4215.
Rob is an author or inventor of over 50 publications and patents and holds a BSc and PhD from the University of Nottingham. |
|
|
György |
|
Keseru |
|
Principal Investigator |
Research Centre for Natural Sciences |
https://proventainternational.com/wp-content/uploads/2022/01/Gyorgy-Keseru.png |
György M. Keserű obtained his Ph.D. at Budapest, Hungary. He worked for Sanofi, then moved to Gedeon Richter and was appointed as the Head of Discovery Chemistry. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been marketed from 2016 in US and EU. In 2013 he established his Medicinal Chemistry Research Group at the Research Center for Natural Sciences, Hungary. He is a full professor at the Budapest University of Technology and Economics. Recently he has been elected as corresponding member of the Hungarian Academy of Sciences. His research interests include medicinal chemistry and drug design. |
|
|
Guido |
|
Koch |
|
Chief Executive Officer |
Amphilix |
https://proventainternational.com/wp-content/uploads/2020/09/Guido-Koch.jpg |
Guido Koch is a board member of SynpleChem and co-founder and CEO of Amphilx. From 2018 to 2020, Guido was the COO of Topadur Pharma and before a Director in Global Discovery Chemistry at Novartis.
During his career in drug discovery and development, Guido has lead projects in different phases from target identification to early clinical stage including multiple kinase inhibitors. Highlights from >20 years of experience in pharmaceutical industry include significant contributions to one marketed product and 8 clinical candidates.
Guido has built a strong network with academia and the CRO community, which allows him to support research programs by external knowledge, new technology and resources. His research has culminated in >45 scientific publications and 10 patent applications.
Educated at ETH Zürich, he received his Diploma in Chemistry and Biochemistry in 1991, followed from a PhD from the University of Basel. After a postdoc at Caltech, he joined Novartis in 1997. |
|
|
Pierre |
|
Morieux |
|
Chemistry Product Marketing Manager |
PerkinElmer |
https://proventainternational.com/wp-content/uploads/2022/05/Morieux-Portrait.jpg |
|
|
|
Garry |
|
Pairaudeau |
|
Chief Technology Officer |
Exscientia |
https://proventainternational.com/wp-content/uploads/2020/02/Garry-Pairaudeau-New.jpg |
Garry Pairaudeau is currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening and DEL is responsible for generating high quality starting points for AstraZeneca. In addition, the group works extensively with academic centres of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc and many others to help support academic drug discovery. Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities.
He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respirator,y inflammation and CV areas. He has a long standing interest in lead generation, innovation, in chemistry, hit identification and diversity screening. Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular research area at Alderley Park.
Specialties: Medicinal Chemistry
Lead Generation
Leadership, Strategy and Change Management
Innovation and Culture Change
Building and managing external relationships
|
|
|
Graham |
|
Simpson |
|
SVP, Drug Discovery |
Dunad Therapeutics |
https://proventainternational.com/wp-content/uploads/2020/02/Graham-Simpson.jpg |
A creative and passionate scientific leader with a strong track record of establishing, driving and delivering innovative drug discovery programs in pharma and biotech. Keen interest in, and appreciation of the broader business challenges facing the pharmaceutical industry; well networked throughout the global pharmaceutical and academic communities. Experienced and ambitious drug discovery leader with 12 years pharmaceutical industry experience. Recognised platform and programme leader, delivering multiple breakthrough innovations and successful discovery milestones. Broad therapeutic area experience and track record of innovation and delivery
Specialties: Chemistry Department Head/Leader, PROTACS, macrocyclic peptides, phenotypic screening, parallel synthesis, complex organic total syntheses, HTS analysis, rational medicinal chemistry and drug design, knowledge-based design, managing CRO workplans, innovative modalities, next-generation in-silico design, artificial intelligence. |
|
|
Marie |
|
Wikstrom Lindholm |
|
SVP, Head of Molecular Design |
Silence Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/01/Marie-Wikstrom-Lindholm.jpeg |
Marie W Lindholm joined Silence Therapeutics in December 2017 as Head of Innovation Technology, leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatocyte siRNA targeting.
Marie got a PhD in Medical Chemistry from Uppsala University, Sweden and later became an Associate Professor in Experimental Cardiovascular Medicine at Lund University. In 2007 Marie joined Santaris Pharma, working on LNA oligonucleotide research. Santaris Pharma was acquired by Roche and Marie was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates.
Marie has authored >50 patents and scientific publications, many in the fields of antisense drug design, safety, and function. |
Radisson Blu Hotel, Stansted Airport
Payment Securely powered by stripe
